5965-66-2

Usage

Uses

Used in Pharmaceutical Industry:
BETA-D-LACTOSE is used as a nutrient and a filler in the pharmaceutical industry for the production of tablets. Its presence in pills provides a source of energy and enhances the overall formulation of the medication.
Used in Food and Beverage Industry:
BETA-D-LACTOSE is used as a sweetening agent in the food and beverage industry, particularly for stout beer. Its natural sweetness adds flavor and enhances the taste of the beverage.
Used in Illicit Drug Preparation:
Although not a legal or ethical application, BETA-D-LACTOSE is utilized in the dilution of heroin, which is an illicit drug. This use highlights the versatility of the compound but also emphasizes the importance of responsible and ethical use of chemicals.

Biochem/physiol Actions

Beta-Lactose is the beta-pyranose form of the compound lactose.

Downstream Products

• 85054-31-5 GlcNAc-β1,6-GalNAc-α1-OBn 
• 87866-15-7 Gal-β1,3[GlcNAc-β1,6]-GalNAc-α1-OBn 
• 74-90-8 hydrogen cyanide 
• 64-18-6 formic acid 
• 849585-22-4 LACTIC ACID 
• 473-90-5 acetonedicarboxylic acid 
• 144-62-7 oxalic acid 
• 499-16-1 lactitol 
• 183811-88-3 β-D-galactopyranosyl-(1->6)-2-acetamido-2-deoxy-β-D-glucopyranose 
• 47491-70-3 β-D-galactopyranosyl-(1->4)-O-2-acetamido-2-deoxy-β-D-glucopyranose 
• 2280-44-6 D-Glucose 
• 10257-28-0 D-Galactose 
• 91887-49-9 1-[(2R,3R,4R,5S,6R)-3,4-Dihydroxy-6-hydroxymethyl-5-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-2-yl]-1-octyl-3-phenyl-thiourea 
• 96-82-2 lactobionic acid 

Relevant academic research and scientific papers

MIXTURE OF FUCOSYLATE LACTOSES

A method to form a mixture containing at least one of 2'-FL (2'-O-fucosyllactose, Fuc(a1-2)Gai(β1-4)Glc) and 3-FL (3-O-fucosyllactose, Gal(β1-4)[Fuc(a1-3)]Glc)characterized in that DFL (difucosyl-lactose, Fuc(a1-2)Gal(β1-4)[Fuc(a1-3)]Glc) is subjected to partial hydrolysis, e.g. enzymatic hydrolysis or acid hydrolysis,

PHARMACEUTICAL ANTIRETROVIRAL COMPOSITION

The present invention relates to a pharmaceutical antiretroviral composition comprising (i) a nucleoside reverse-transcriptase inhibitor selected from lamivudine and emtricitabine, (ii) extended release nevirapine, and (iii) tenofovir; a process for preparing such composition and the use of such composition in medicine, particularly for the prophylaxis and/or treatment of diseases caused by retroviruses.

Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract

Disclosed herein is a pharmaceutical composition having preventative and therapeutic effects on liver diseases, comprising an extract from Lonicera caerulea L. var. edulis. The composition has preventative and therapeutic effects on hepatitis, liver cirrhosis, fatty liver, and the like.

Synthesis and characterization of bis(glycosylamino)benzenes based on reducing disaccharides

Synthesis of bis(glycosylamino)benzenes, derived from disaccharides lactose, maltose, and cellobiose, by direct condensation and their characterization are described.

Popping oral pharmaceutical compositions

Disclosed are popping pharmaceutical compositions, which comprise OTC or prescription drug, and popping material. The popping material includes pressurized gas trapped within cavities of a pharmaceutically acceptable material in a manner that allows the gas to escape from the pharmaceutical composition upon dissolution, contact with saliva or shattering of the popping material. Such an oral pharmaceutical composition may be popular with children that will prefer it on other ones, which do not pop. Methods for preparation of such oral pharmaceutical compositions are also disclosed.

Modified carrier particles for use in dry powder inhalers

The invention relates to carrier particles for use in pharmaceutical compositions for the pulmonary administration of medicaments by means of dry powder inhalers. In particular, the invention relates to a novel technological process for obtaining a carrier modified so as to improve the efficiency of redispersion of active particles and hence increase the respirable fraction. After the treatment of the invention, the surface of said modified carrier particles can also be coated with a suitable additive so as to further improve the respirable fraction.

Preventives and remedies for medicinal and alcoholic poisoning

Preventives or remedies for medicinal and alcoholic poisoning contain as a pharmaceutically effective component phytic acid or its salt which may be an innoxious metal salt, or an innoxious salt with an organic base, a basic amino acid or an organic ester residue.

Anti-hypertensive substituted 2-azabicyclooctane-3-carboxylic acids

Compounds of formula (I): STR1 in which E denotes a lower alkyl group, or preferably a hydrogen atom, and their addition salts with a pharmaceutically acceptable acid or base, the preparation thereof and pharmaceutical compositions containing them.

Granular delayed-release form of pharmaceutically active substances

A granular delayed-release form of pharmaceutically active substances, which is prepared by coating a granulated or crystalline pharmaceutically active substance, or mixtures thereof, with a coating material mixture consisting essentially of a homogeneous mixture of a poly(H+meth)-acrylic acid-(methyl+ethyl)ester which is insoluble but dispersible in water and an ethyl cellulose which is insoluble but dispersible in water in the weight ratio of 20:1 to 1:5, is presented, which is characterized by the fact that the coated granules are heated for at least 5 minutes at elevated temperatures ranging from between 50° to 120° C.